Weekly FDA Roundup: Hospital Drug Mix-Up, Natural Dye Delays, and a Cancer "Vaccine" Warning — Week of March 21–28, 2026

18 regulatory actions this week. Six warning letters, three recalls, three rules, two press release approvals, two device safety alerts, and two administrative notices.

---

Critical Recall: Amneal Pharmaceuticals Drug Mix-Up

The week's most urgent action isn't a warning letter or a guidance update — it's a hospital-level pharmaceutical recall with direct patient safety stakes.

Amneal Pharmaceuticals voluntarily recalled one lot (AH250162) of Magnesium Sulfate in Water for Injection, USP (4g/100mL) after discovering that a pouch within the carton contained Tranexamic Acid in 0.7% Sodium Chloride Injection (10mg/mL) instead. The lot was distributed nationwide to wholesalers and distributors between December 22, 2025, and February 27, 2026.

The risk is real and bilateral. If a patient with preeclampsia or eclampsia fails to receive magnesium in time, life-threatening seizures can follow. If TXA is inadvertently administered, it can cause blood clotting, seizures, and hypersensitivity reactions. No adverse events have been reported as of the recall date. FDA's assessment is that hospital medication-administration controls provide multiple safety checks that make patient exposure unlikely — but the mix-up reaching this far in the supply chain is itself the problem.

---

Warning Letters: Six Issued, Three Themes

Promotional overreach (OPDP): The FDA's Office of Prescription Drug Promotion issued a warning letter to ImmunityBio, Inc. over promotion of ANKTIVA, its intravesical bladder cancer drug. The violations center on a direct-to-consumer TV ad and a podcast in which ImmunityBio's executive chairman Patrick Soon-Shiong stated that ANKTIVA "can treat all cancers," functions as a "cancer vaccine," and can be administered subcutaneously. The drug is approved for one indication: BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Intravesical use only. This letter follows untitled letters to a subsidiary in September 2025 and January 2026. The pattern of escalating enforcement suggests FDA had already signaled compliance expectations before resorting to a formal warning. ImmunityBio's stock fell roughly 25% on the news.

Source: ImmunityBio Warning Letter

Unauthorized device expansion (CDRH): FDA issued a warning letter to Longhorn Vaccines and Diagnostics LLC for marketing its PrimeStore MTM device for the stabilization and inactivation of Ebola, Mpox, and antimicrobial resistance (AMR) gene detection — none of which were covered under its existing clearance. FDA found systemic QSR failures alongside the unauthorized expansion: inadequate CAPA procedures, failure in complaint handling, and supplier management gaps.

Source: Longhorn Vaccines Warning Letter

Unauthorized device distribution (CBER): FDA cited 4U Health for distributing an HIV dried blood spot (DBS) self-collection kit without an approved PMA, IDE, or 510(k) clearance. The device is considered adulterated and misbranded under FD&C Act Section 515(a). 4U Health has 15 working days to respond with a corrective action plan.

Source: 4U Health Warning Letter

Unauthorized tobacco products (CTP): matesbrand.com received a letter for selling Pouchmates Nicotine Pouches without required premarket authorization under the Family Smoking Prevention and Tobacco Control Act. The company has ties to 7D Holdings LLC and 7 Daze LLC. FDA's letter was directed to the business and its platform infrastructure, consistent with the agency's pattern of pulling in downstream facilitators (Shopify, GoDaddy) when pursuing unauthorized online tobacco sellers.

Source: matesbrand.com Warning Letter

CGMP violations — OTC drugs (CDER): Yangzhou H&R Plastic Daily Chemical Co., Ltd. (China) was cited for failing to test OTC drug product batches for active ingredient identity and strength prior to release, failing to perform identity testing on incoming components, lacking process validation, and maintaining an inadequate quality unit. The firm's products are now on Import Alert 66-40, meaning FDA can detain future shipments without physical examination.

Source: Yangzhou H&R Warning Letter

CGMP violations — medical devices (CDRH): IsoTis OrthoBiologics, Inc. was cited for QSR violations related to resorbable calcium salt bone void fillers and demineralized bone matrix (DBM). Core findings: inadequate CAPA for particulate contamination from equipment shedding, failure to revalidate the demineralization process after equipment changes, and failure to update risk analysis files to reflect the particulate hazard.

Source: IsoTis Warning Letter

---

Natural Color Additives: Two Effective Dates Delayed Indefinitely

FDA announced indefinite delays to the effective dates for two color additive final orders it published on February 6, 2026: the approval of beetroot red and the expanded use of spirulina extract in human foods.

Both were enabled by the current administration's push to move away from synthetic food dyes — the same policy direction driving the agency's recent moves against petroleum-based food colorings. The effective dates are now delayed indefinitely, held up by timely objections that triggered a mandatory hearing process:

• Beetroot red was challenged by GMO/Toxin Free USA, which argued the colorant does not qualify as "natural" because it is produced using genetically engineered synthetic biology technology.
• Spirulina extract was challenged by Obelisk Tech Systems — a national defense and cybersecurity contractor — which raised national security, recordkeeping, and public health concerns about the expansion, and disputed the adequacy of safety data.

FDA maintains both additives are safe for their intended uses. Product reformulations contingent on these approvals are stalled until the hearing process resolves — no timeline has been set.

Sources: Beetroot Red Delay (Federal Register) Spirulina Extract Delay (Federal Register)

---

Device Recalls: Two Class I Actions

Erbe USA Flexible Cryoprobes (Class I): Erbe USA recalled multiple models of flexible cryoprobes after discovering a manufacturing defect — insufficient adhesive application — that allows the probes to rupture or burst during activation. The rupture can cause loud sounds leading to permanent hearing loss or tinnitus, and physical burns to patients and healthcare personnel. FDA has logged five serious injuries associated with this defect.

Source: Erbe USA Recall

Navajo Manufacturing Heating Pads (Class I): The Handy Solutions Neck & Shoulders Heating Pad (Model 25607) was recalled for burn and fire risk. The device can reach hazardous temperatures when folded during use and lacks an automatic shutoff. FDA advises immediate discontinuation and disposal.

Source: Navajo Manufacturing Recall

---

Supplement and Food Recalls

Vital Nutrients Aller-C (allergy): Blueroot Health recalled two lots (25E04-A and 25E04-B) of Vital Nutrients Aller-C dietary supplements for undeclared egg, hazelnut, and soy. The allergens were discovered during routine internal testing. Products were distributed nationwide via online retailers. For companies in the supplement space, this is a labeling and testing process issue — not a supplier problem.

Source: Blueroot Health Recall

Falcon Trading Company Organic Black Beans (pesticide): Recalled bulk black beans, chili bean blends, and soup mixes after routine testing found pesticide residue in products sourced from a certified organic handler. Sold under Falcon Trading Company and SRF brands.

Source: Falcon Trading Recall

---

FDA Approvals: Two Rare Pediatric Drugs

Kresladi (Rocket Pharmaceuticals): FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I) in pediatric patients without an available HLA-matched sibling donor. LAD-I leaves children unable to mount an adequate immune response to bacterial infections. Kresladi uses autologous hematopoietic stem cells modified to restore ITGB2 gene function. Approval was based on a surrogate endpoint (CD18/CD11a expression in neutrophils); post-marketing trials to verify clinical benefit are required. Rocket also received a Rare Pediatric Disease Priority Review Voucher. An initial BLA submission was rejected in 2024 over manufacturing concerns.

Source: FDA Press Release

Avlayah (Denali Therapeutics): FDA granted accelerated approval to Avlayah (tividenofusp alfa-eknm), a weekly IV infusion for neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. The surrogate endpoint was reduction of heparan sulfate in cerebrospinal fluid. Labeling includes a boxed warning for anaphylaxis; providers are instructed to monitor for anemia and membranous nephropathy.

Source: FDA Press Release

---

Regulatory Actions to Note

Skin lesion diagnostic device reclassification: FDA finalized a reclassification of optical diagnostic devices for melanoma detection and electrical impedance spectrometers, renaming them "Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer" under 21 CFR Part 878. The rename reflects increased specificity about intended user qualifications — which has implications for both device labeling and physician training documentation.

Source: Federal Register Final Order

Commissioner's National Priority Voucher (CNPV) Pilot: FDA published a notice of public hearing and request for comments on a proposed pilot program to incentivize development of priority medical products. The CNPV would function as a new type of regulatory incentive distinct from the existing Priority Review Voucher structure. Public comments are open. Companies developing products that could qualify as national priorities should review the docket and consider submitting comments before the deadline closes.

Source: CNPV Notice (Federal Register)

Elite Laboratories ANDA correction: FDA issued a correction to an earlier notice withdrawing approval of 72 ANDAs held by Elite Laboratories, Inc., et al. The underlying withdrawals stand; this is a technical correction to the published record.

Source: Federal Register Notice

---

Policy Canary monitors FDA enforcement actions, recalls, warning letters, and regulatory changes so your compliance team doesn't have to. Start your free trial at policycanary.io